Should I Buy NAMS? NAMS 2026 Analysis

Should You Buy NewAmsterdam Pharma Company NV (NAMS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

34.300

1 Day change

6.99%

52 Week Range

42.000

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: there’s no proprietary buy signal, no near-term news catalyst, and price is sitting just below the pivot (32.58) with only modest bullish momentum.
If you must act quickly, the higher-probability setups are (1) a clean break/hold above 34.28 (R1) for momentum continuation, or (2) a pullback closer to 30.88 (S1) for a better risk-defined entry.
Options activity shows conflicting sentiment (bullish OI structure but heavy put volume today), reinforcing a “wait for confirmation” stance rather than chasing.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: MACD histogram is positive (0.137) and expanding, indicating improving upside momentum.
RSI: RSI(6) ~53.4 (neutral), so momentum isn’t overbought and also not strongly trending yet.
Moving averages: Converging MAs suggests consolidation/indecision rather than a clean trend.
Levels to watch: Pivot 32.584 (price 32.27 is slightly below); resistance at 34.284 (R1) then 35.334 (R2); support at 30.884 (S1) then 29.834 (S2).
Near-term pattern stats (similar candlestick analogs): modeled odds favor upside skew (approx. +2.92% next day, +8.87% next week, +5.78% next month), but this needs confirmation via a pivot reclaim and/or R1 breakout.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

Positioning (Open Interest): Put/Call OI ratio 0.82 (more calls than puts) is mildly bullish.
Flow (Today’s Volume): Put/Call volume ratio 8.0 indicates put-heavy trading today (bearish/hedging tone), though absolute volume is small (9 contracts total).
Volatility: 30D IV 68.56 vs HV 42.25 suggests options price in elevated forward uncertainty.
IV percentile/rank: IV percentile 14 / IV rank 13.78 = relatively low versus its own history (options comparatively “cheap” vs recent range).
Activity: Today’s volume vs 30D average is elevated (7.5x), but from a low base; treat as a sentiment hint, not a definitive signal.

Technical Summary

Sell

Buy

Positive Catalysts

on 2026-01-
- Technical momentum improving: positive, expanding MACD suggests building upside pressure if price reclaims/holds above the pivot.

Neutral/Negative Catalysts

- No news in the past week: limited event-driven catalyst for an immediate move.
- Price is below the pivot (32.58): until reclaimed, upside attempts may stall.
- Options volume skew is put-heavy today (put/call volume 8.0), suggesting near-term caution/hedging.
- Institutional/insider signals are neutral: no strong “smart money” urgency indicated recently.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: $348K, down -98.80% YoY (very weak top-line, consistent with development-stage biotech dynamics).
Earnings/Loss profile: Net income reported at -$72.0M (still deeply negative). EPS -0.61, improved +238.89% YoY (loss per share narrowed versus prior year).
Gross margin: 100% (not very informative at this revenue scale; overall story remains centered on pipeline execution rather than current sales).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

2026-01-21: RBC Capital raised price target to $47 from $44 and maintained an Outperform rating.
Wall Street pros: supportive sell-side stance with higher target implies confidence in longer-term upside/pipeline execution.
Wall Street cons: target/rating support is not paired with a near-term catalyst in current data; stock action still needs technical confirmation above key resistance for an impatient entry.

10 Analyst Rating

Wall Street analysts forecast NAMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAMS is 48.63 USD with a low forecast of 37 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 32.060

Low

Averages

48.63

High

Current: 32.060

Low

Averages

48.63

High

RBC Capital

Outperform

upgrade

$44 -> $47

AI Analysis

2026-01-21

Reason

RBC Capital

Price Target

$44 -> $47

AI Analysis

2026-01-21

upgrade

Outperform

Reason

RBC Capital raised the firm's price target on NewAmsterdam Pharma to $47 from $44 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.

H.C. Wainwright

Joseph Pantginis

initiated

$52

2025-10-20

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

$52

2025-10-20

initiated

Reason

H.C. Wainwright analyst Joseph Pantginis assumed coverage of NewAmsterdam Pharma with a Buy rating and $52 price target. NewAmsterdam is a late clinical-stage biopharmaceutical company developing obicetrapib, a non-statin, next-generation cholesterol ester transfer protein small molecule inhibitor for low-density lipoprotein cholesterol reduction, the analyst tells investors in a research note. The firm says obicetrapib is :poised to burst into the lipid-lowering space."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NAMS

Unlock Now

NAMS Should I Buy

NAMS Should I Buy

Should You Buy NewAmsterdam Pharma Company NV (NAMS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch